AIA
BMRN icon

Alera Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alera Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19
Closed -$2K – 1190
2018
Q4 		$2K Buy
+19
New +$1.81K ﹤0.01% 730

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alera Investment Advisors's BMRN Position: Q1 2019 in Review

Alera Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 19 shares — an estimated $2K sold.

Alera Investment Advisors first reported a position in BMRN in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

  • Alera Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 19 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $2K.
  • Alera Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Alera Investment Advisors's BioMarin Pharmaceuticals position peaked at $2K in Q4 2018.
  • 486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Alera Investment Advisors's 13F filing for Q1 2019, filed 14 May 2019.